{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:23:04Z","timestamp":1790882584194,"version":"4.1.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.juro.2007.09.003","type":"journal-article","created":{"date-parts":[[2007,11,10]],"date-time":"2007-11-10T07:15:37Z","timestamp":1194678937000},"page":"2314-2330","source":"Crossref","is-referenced-by-count":623,"title":["Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update"],"prefix":"10.1097","volume":"178","author":[{"given":"M. Craig","family":"Hall","sequence":"first","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Som","family":"Pruthi","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Derek","family":"Seigne","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eila Curlee","family":"Skinner","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Wolf","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Schellhammer","sequence":"additional","affiliation":[{"name":"American Urological Association Education and Research, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2007.09.003_bib1","series-title":"Cancer Facts and Figures 2007","year":"2007"},{"key":"10.1016\/j.juro.2007.09.003_bib2","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","article-title":"Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis)","volume":"162","author":"Smith","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib3","unstructured":"Oosterlinck W, van der Meijden A, Sylvester R, B\u00f6hle A, Rintala E, Solsona Narv\u00f3n E et al: Guidelines on TaT1 (non-muscle invasive) bladder cancer. http:\/\/www.uroweb.org\/nc\/professional-resources\/guidelines\/online\/. Accessed September 4, 2007."},{"key":"10.1016\/j.juro.2007.09.003_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1063-5777(05)70062-1","article-title":"Transurethral resection of bladder cancer","volume":"5","author":"Shelfo","year":"1997","journal-title":"Atlas Urol Clin North Am"},{"key":"10.1016\/j.juro.2007.09.003_bib5","series-title":"Comprehensive Textbook of Genitourinary Oncology","first-page":"405","article-title":"Natural history and surgical management of superficial bladder cancer (stages Ta\/T1\/CIS)","author":"Koch","year":"1996"},{"key":"10.1016\/j.juro.2007.09.003_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0094-0143(21)00225-1","article-title":"Endoscopic applications of laser energy","volume":"13","author":"Smith","year":"1986","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2007.09.003_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.ju.0000103100.22951.5e","article-title":"Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm","volume":"171","author":"Donat","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"Bouffioux","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib12","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2007.09.003_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.juro.2007.09.003_bib16","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.juro.2007.09.003_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systemtic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2007.09.003_bib18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib19","series-title":"Campbell\u2019s Urology","first-page":"2327","article-title":"Urothelial tumors of the urinary tract","author":"Messing","year":"1998"},{"key":"10.1016\/j.juro.2007.09.003_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0022-5347(01)67650-X","article-title":"Carcinoma in situ of the bladder","volume":"153","author":"Hudson","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib21","first-page":"947","article-title":"BCG immunotherapy for transitional-cell carcinoma in situ of the bladder","volume":"9","author":"Lamm","year":"1995","journal-title":"Oncology"},{"key":"10.1016\/j.juro.2007.09.003_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2005.05.011","article-title":"EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ","volume":"48","author":"van der Meijden","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1988.6.3.476","article-title":"Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study","volume":"6","author":"Torti","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0090-4295(96)00375-5","article-title":"Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer","volume":"48","author":"Stricker","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.003_bib25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1179\/joc.2002.14.2.194","article-title":"Combined low dose intravesical immuno-therapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up","volume":"14","author":"Mohanty","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.juro.2007.09.003_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-5347(17)55018-1","article-title":"The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder","volume":"125","author":"Koontz","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0022-5347(17)38152-1","article-title":"Phase 1\/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder","volume":"146","author":"Kurth","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib32","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplastin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic blader cancer: results of a large, randomized multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.003_bib34","first-page":"2493","article-title":"Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharacokin- etic study","volume":"25","author":"Mattioli","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.juro.2007.09.003_bib35","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.mou.0000240310.70582.ce","article-title":"Intravesical gemcitabine: an update of clinical results","volume":"16","author":"Hendricksen","year":"2006","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1287\/opre.37.2.210","article-title":"The confidence profile method: a Bayesian method for assessing health technologies","volume":"37","author":"Eddy","year":"1989","journal-title":"Oper Res"},{"key":"10.1016\/j.juro.2007.09.003_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S0266462300008928","article-title":"A Bayesian method for synthesizing evidence","volume":"6","author":"Eddy","year":"1990","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.juro.2007.09.003_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1464-410X.1976.tb02742.x","article-title":"Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma","volume":"48","author":"Burnand","year":"1976","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-5347(17)52205-3","article-title":"Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial","volume":"129","author":"Zincke","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1464-410X.1997.00142.x","article-title":"Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study","volume":"79","author":"Ali-el-Dein","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib45","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1136\/bmj.296.6639.1759","article-title":"Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)","volume":"296","author":"Tolley","year":"1988","journal-title":"Br Med J"},{"key":"10.1016\/j.juro.2007.09.003_bib46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2007.09.003_bib50","doi-asserted-by":"crossref","first-page":"s72","DOI":"10.1007\/BF00262491","article-title":"Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer","volume":"20","author":"Tsushima","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.juro.2007.09.003_bib51","doi-asserted-by":"crossref","first-page":"s85","DOI":"10.1007\/BF00262494","article-title":"Prophylactic treatment for superficial bladder cancer following transurethral resection","volume":"20","author":"Hirao","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.juro.2007.09.003_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000474054","article-title":"Mitomycin instillation to prevent recurrence of superficial bladder carcinoma","volume":"9","author":"Huland","year":"1983","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib53","doi-asserted-by":"crossref","first-page":"s15","DOI":"10.1007\/BF00686935","article-title":"Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin","volume":"30","author":"Akaza","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.juro.2007.09.003_bib54","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","article-title":"Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial","volume":"138","author":"Hudson","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib57","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib58","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer?","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.003_bib59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib60","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2007.09.003_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2007.09.003_bib62","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib63","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-5347(05)65969-1","article-title":"Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib65","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1464-410X.2006.06144.x","article-title":"The value of second transurethral resection for T1 bladder cancer","volume":"97","author":"Schwaibold","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2007.09.003_bib66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0022-5347(05)66532-9","article-title":"Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy of ten too early?","volume":"165","author":"Brauers","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib67","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/00365590410029141","article-title":"Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder","volume":"38","author":"May","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.juro.2007.09.003_bib69","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib70","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2007.09.003_bib71","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.ju.0000136294.15938.3d","article-title":"Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy","volume":"172","author":"Hassan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib72","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/0959-8049(95)00287-S","article-title":"Factors affecting recurrence and progression in superficial bladder tumours","volume":"31A","author":"Kurth","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2007.09.003_bib73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-5347(17)38731-1","article-title":"Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)","volume":"143","author":"Parmar","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma of the bladder: results of a European Organization for the Research and Treatment of Cancer \u2013 Genito-Urinary Group Phase III Trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2007.09.003_bib78","unstructured":"CONSORT guidelines. http:\/\/www.consort-statement.org. Accessed September 4, 2007."}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002253470702397X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002253470702397X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2007.09.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:27:37Z","timestamp":1784910457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.juro.2007.09.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1016\/j.juro.2007.09.003"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2007.09.003","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}